Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Patrick R. O'neil Sells 6,165 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Patrick R. O'neil sold 6,165 shares of the company's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the sale, the executive vice president now owns 57,452 shares of the company's stock, valued at $1,816,632.24. This represents a 9.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ionis Pharmaceuticals Stock Up 0.0 %

Shares of Ionis Pharmaceuticals stock traded up $0.01 during trading on Monday, reaching $31.41. The company had a trading volume of 386,825 shares, compared to its average volume of 1,576,330. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $31.03 and a fifty-two week high of $52.34. The firm's fifty day moving average is $34.79 and its 200-day moving average is $39.50. The company has a market cap of $4.96 billion, a price-to-earnings ratio of -12.86 and a beta of 0.34.

Institutional Trading of Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Nicollet Investment Management Inc. increased its holdings in shares of Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company's stock valued at $817,000 after acquiring an additional 294 shares during the last quarter. Amalgamated Bank boosted its holdings in Ionis Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 9,957 shares of the company's stock worth $399,000 after purchasing an additional 300 shares during the period. GAMMA Investing LLC increased its stake in Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock valued at $27,000 after purchasing an additional 303 shares during the last quarter. Itau Unibanco Holding S.A. raised its holdings in shares of Ionis Pharmaceuticals by 40.9% during the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company's stock worth $43,000 after purchasing an additional 314 shares during the period. Finally, Bleakley Financial Group LLC lifted its position in shares of Ionis Pharmaceuticals by 2.1% in the 3rd quarter. Bleakley Financial Group LLC now owns 16,678 shares of the company's stock worth $668,000 after buying an additional 338 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Royal Bank of Canada restated an "outperform" rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, January 15th. William Blair restated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Piper Sandler dropped their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. StockNews.com downgraded Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, November 12th. Finally, Wells Fargo & Company decreased their target price on Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a research report on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.